Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

Learn more about:
Related Clinical Trial
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma Establishment and Clinical Application of Risk Classification Model Based on Molecular Typing of Medulloblastoma in Children GD2-CAR T Cells for Pediatric Brain Tumours Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors or Meningiomas Expressing SST2A Effect of Metformin on Behaviour and the Brain in Children Treated for a Brain Tumour NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors Quantitative Assessment of Radiation-induced Neuroinflammation – A Proof of Principle Study Efficacy of Dual Task Training on Children With Ataxia After Medulloblastoma Resection Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma Dual Task Training On Children With Ataxia After Medulloblastoma Resection Clinical Trial to Assess the Safety and Efficacy of AloCELYVIR With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Combination With Radiotherapy or Medulloblastoma in Monotherapy 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma Eflornithine (DFMO) for Medulloblastoma Physical Activity on Postural Stability and Coordination in Children With Posterior Fossa Tumor Apatinib Combined With Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children Volitinib in Treating Participants With Recurrent or Refractory Primary CNS Tumors Phase I Study of APX005M in Pediatric CNS Tumors Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors Dosimetry Guided PRRT With 90Y-DOTATOC A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors Valproic Acid in Childhood Progressive Brain Tumors Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors AflacST1901: Peds WP1066 An East Asian Study of LDE225 Immuno 1: Immune Reconstitution Following Conventional or High-Dose Chemotherapy With Stem Cell Transplant Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors Child’s Study of the Impact of PF Lesion on Motor Skills, Language, Cognitive Functioning and Social Cognition Theranostics: 68GaDOTATOC and 90YDOTATOC Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG Fimepinostat in Treating Brain Tumors in Children and Young Adults A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs Combination of Irinotecan and Temozolomide in Children With Brain Tumors. A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma Multicenter Register for Children and Young Adults With Intracranial Localized Medulloblastoma, CNS-PNET or Ependymoma Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor HeadStart4: Newly Diagnosed Children ( Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma Multicenter Pilot-study for the Therapy of Medulloblastoma of Adults Infusion of Panobinostat (MTX110) Into the Fourth Ventricle in Children and Adults With Recurrent Medulloblastoma Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma Children’s and Adolescents’ Medulloblastoma Molecular Subgroups in China Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET Hyperfractionated Versus Conventionally Fractionated Radiotherapy in Standard Risk Medulloblastoma Social Cognition and Brain Integrity in Survivors of Pediatric Medulloblastoma Study of Tomotherapy HD in Medulloblastoma

Recruitment Information


Administrative Informations